Sarepta Therapeutics (NASDAQ:SRPT) Hits New 1-Year Low - Here's Why

Sarepta Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Sarepta shares hit a new 52-week low, trading as low as $14.59 and last at $14.72, down from the prior close of $15.13.
  • Analyst sentiment is mixed: six rate the stock Buy, six Hold, and six Sell; the consensus rating is Hold with an average price target of $23.67.
  • The company beat quarterly earnings and revenue expectations, reporting $0.13 per share and $381.35 million in revenue, though revenue fell 4.5% year over year.
  • Five stocks we like better than Sarepta Therapeutics.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday. The company traded as low as $14.59 and last traded at $14.72, with a volume of 542,419 shares traded. The stock had previously closed at $15.13.

Analyst Ratings Changes

SRPT has been the subject of a number of research reports. Needham & Company LLC reaffirmed an "underperform" rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. Robert W. Baird set a $18.00 price objective on Sarepta Therapeutics in a research note on Friday, November 6th. Royal Bank Of Canada increased their price target on shares of Sarepta Therapeutics from $17.00 to $18.00 and gave the company a "sector perform" rating in a research report on Friday, November 6th. JPMorgan Chase & Co. lowered their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating on the stock in a report on Wednesday, September 30th. Finally, Deutsche Bank raised shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating and lifted their price objective for the stock from $14.00 to $18.00 in a research report on Tuesday, November 10th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $23.67.

Get Our Latest Report on Sarepta Therapeutics

Sarepta Therapeutics Trading Down 2.3%

The company has a 50 day moving average of $18.44 and a two-hundred day moving average of $18.48. The stock has a market capitalization of $1.58 billion, a PE ratio of -10.79, a P/E/G ratio of 0.38 and a beta of 0.45. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.13 and a current ratio of 3.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.05. Sarepta Therapeutics had a negative return on equity of 0.20% and a negative net margin of 5.86%. The company had revenue of $381.35 million during the quarter, compared to analysts' expectations of $352.20 million. During the same period last year, the business posted ($0.13) earnings per share. The firm's revenue was down 4.5% compared to the same quarter last year. Sell-side analysts predict that Sarepta Therapeutics, Inc. will post 3.27 EPS for the current year.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its stake in shares of Sarepta Therapeutics by 60.4% during the third quarter. Goldman Sachs Group Inc. now owns 3,277,091 shares of the biotechnology company's stock worth $59,709,000 after buying an additional 1,234,590 shares during the period. Empowered Funds LLC increased its position in shares of Sarepta Therapeutics by 195.2% in the 3rd quarter. Empowered Funds LLC now owns 562,573 shares of the biotechnology company's stock valued at $10,250,000 after acquiring an additional 371,987 shares during the period. First Trust Advisors LP raised its stake in Sarepta Therapeutics by 12.8% in the 3rd quarter. First Trust Advisors LP now owns 4,923,020 shares of the biotechnology company's stock worth $89,697,000 after acquiring an additional 557,069 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Sarepta Therapeutics in the 3rd quarter worth $87,000. Finally, Voya Investment Management LLC raised its stake in Sarepta Therapeutics by 228.7% in the 3rd quarter. Voya Investment Management LLC now owns 213,046 shares of the biotechnology company's stock worth $3,882,000 after acquiring an additional 148,228 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company's DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sarepta Therapeutics Right Now?

Before you consider Sarepta Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.

While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines